M
MIRA
vs
S&P 500
S&P 500
Over the past 12 months, MIRA has significantly outperformed S&P 500, delivering a return of +38% compared to the S&P 500's +16% growth.
Stocks Performance
MIRA vs S&P 500
Performance Gap
MIRA vs S&P 500
Performance By Year
MIRA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mira Pharmaceuticals Inc
Glance View
Mira Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Baltimore, Maryland and currently employs 1 full-time employees. The company went IPO on 2023-08-03. MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The firm is focused on the development and commercialization of molecular synthetic cannabinoid analog for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. The firm is developing its product candidate, MIRA1a, for the treatment of neuropsychiatric, inflammatory and neurologic diseases and disorders. MIRA1a is a synthetic cannabinoid analog for treating anxiety and chronic pain by striking a balance between the beneficial effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors.